ArticleThe American journal of pathology2010
Olfactomedin-4 regulation by estrogen in the human endometrium requires epidermal growth factor signaling.
Article in The American journal of pathology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Schizophrenia gene expression profile reverted to normal levels by antipsychotics.The international journal of neuropsychopharmacology · 2014Trial
- PCOS endometrium-derived epithelial organoids as a novel model to study endometrial dysfunction.Human reproduction (Oxford, England) · 2025Article
- Unraveling the interrelationship between breast cancer and endometriosis based on multi-omics analysis.Discover oncology · 2025Article
- Article
- Olfactomedin 4 produces dysplasia but suppresses metastasis of colon cancer.Cancer gene therapy · 2023Article
- Basolateral secretions of human endometrial epithelial organoids impact stromal cell decidualization.Molecular human reproduction · 2023Article
- Human Myometrial and Uterine Fibroid Stem Cell-Derived Organoids for Intervening the Pathophysiology of Uterine Fibroid.Reproductive sciences (Thousand Oaks, Calif.) · 2022Article
- Olfactomedin-4 improves cutaneous wound healing by promoting skin cell proliferation and migration through POU5F1/OCT4 and ESR1 signalling cascades.Cellular and molecular life sciences : CMLS · 2022Article
- Self-renewing endometrial epithelial organoids of the human uterus.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Olfactomedin domain-containing proteins: evolution, functional divergence, expression patterns and damaging SNPs.Molecular genetics and genomics : MGG · 2019Article
- Estrogen receptor-mediated miR-486-5p regulation of OLFM4 expression in ovarian cancer.Oncotarget · 2016Article
- Article
- Plasma levels of OLFM4 in normals and patients with gastrointestinal cancer.Journal of cellular and molecular medicine · 2015Article
- Oestrogen receptor-mediated expression of Olfactomedin 4 regulates the progression of endometrial adenocarcinoma.Journal of cellular and molecular medicine · 2014Article
- Olfactomedin proteins: central players in development and disease.Frontiers in cell and developmental biology · 2014Review
- Towards endometriosis diagnosis by gadofosveset-trisodium enhanced magnetic resonance imaging.PloS one · 2012Article
- Endometriosis expresses a molecular pattern consistent with decreased retinoid uptake, metabolism and action.Human reproduction (Oxford, England) · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Olfactomedin-4 (OLFM-4) is an extracellular matrix protein that is highly expressed in human endometrium. We have examined the regulation and function of OLFM-4 in normal endometrium and in cases of endometriosis and endometrial cancer. OLFM-4 expression levels are highest in proliferative-phase endometrium, and 17β-estradiol up-regulates OLFM-4 mRNA in endometrial explant cultures. Using the luciferase reporter under control of the OLFM-4 promoter, it was shown that both 17β-estradiol and OH-tamoxifen induce luciferase activity, and epidermal growth factor receptor-1 is required for this estrogenic response. In turn, EGF activates the OLFM-4 promoter, and estrogen receptor-α is needed for the complete EGF response. The cellular functions of OLFM-4 were examined by its expression in OLFM-4-negative HEK-293 cells, which resulted in decreased vimentin expression and cell adherence as well as increased apoptosis resistance. In cases of endometriosis and endometrial cancer, OLFM-4 expression correlated with the presence of epidermal growth factor receptor-1 and estrogen receptor-α (or estrogen signaling). An increase of OLFM-4 mRNA was observed in the endometrium of endometriosis patients. No change in OLFM-4 expression levels were observed in patients with endometrial cancer relative with controls. In conclusion, cross-talk between estrogen and EGF signaling regulates OLFM-4 expression. The role of OLFM-4 in endometrial tissue remodeling before the secretory phase and during the predisposition and early events in endometriosis can be postulated but requires additional investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.